Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Pharmalot
Biotech
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Biogen earnings lack blockbuster acquisition pop, but executives pledge to keep looking

  • Adam Feuerstein

By Adam Feuerstein Jan. 25, 2018

Reprints
Michel Vounatsos
Biogen CEO Michel Vounatsos Biogen

Biogen (BIIB) bought an early-stage ALS drug Thursday, so cue up the “sad trombones” if you were hoping for a blockbuster biotech acquisition.

But Spinraza sales rebounded nicely in the fourth quarter and the multiple sclerosis business remains in good shape. Biogen offered 2018 financial guidance a tick higher than consensus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
In patients under hypnosis, scientists find distinctive patterns in…
In patients under hypnosis, scientists find distinctive patterns in the brain
J&J loses a patent battle in India over a…
J&J loses a patent battle in India over a crucial tuberculosis drug
Pharmalittle: FDA panel backs conditional approval for Biogen ALS…
Pharmalittle: FDA panel backs conditional approval for Biogen ALS drug; pharma fights tactic for lowering specialty…
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’…
Key senators blast Medicare Advantage insurers for ‘exorbitant salaries,’ ‘massive payouts’ to execs

Recommended Stories